{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:10:20Z","timestamp":1793398220125,"version":"4.5.0"},"reference-count":143,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.canlet.2023.216121","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T20:34:28Z","timestamp":1678221268000},"page":"216121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy"],"prefix":"10.1016","volume":"559","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8227-7166","authenticated-orcid":false,"given":"Brendan","family":"Moran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Davern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John V.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel E.","family":"Donlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3363-3763","authenticated-orcid":false,"given":"Joanne","family":"Lysaght","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.canlet.2023.216121_bib1","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a019505","article-title":"Epigenetic determinants of cancer","volume":"8","author":"Baylin","year":"2016","journal-title":"Cold Spring Harbor Perspect. Biol."},{"issue":"1","key":"10.1016\/j.canlet.2023.216121_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/2045-3701-4-45","article-title":"Epigenetic regulation in cancer progression","volume":"4","author":"Baxter","year":"2014","journal-title":"Cell Biosci."},{"key":"10.1016\/j.canlet.2023.216121_bib3","article-title":"The roles of histone deacetylases and their inhibitors in cancer therapy","volume":"8","author":"Li","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"4","key":"10.1016\/j.canlet.2023.216121_bib4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.molcel.2008.07.002","article-title":"Lysine acetylation: codified crosstalk with other posttranslational modifications","volume":"31","author":"Yang","year":"2008","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.canlet.2023.216121_bib5","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/sj.embor.7400977","article-title":"Metabolism, cytoskeleton and cellular signalling in the grip of protein Nepsilon - and O-acetylation","volume":"8","author":"Yang","year":"2007","journal-title":"EMBO Rep."},{"key":"10.1016\/j.canlet.2023.216121_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2015.00108","article-title":"The role of histone acetyltransferases in normal and malignant hematopoiesis","volume":"5","author":"Sun","year":"2015","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.canlet.2023.216121_bib7","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.canlet.2023.216121_bib8","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: the histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harbor Perspect. Biol."},{"issue":"1","key":"10.1016\/j.canlet.2023.216121_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2023.216121_bib10","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.semcancer.2020.07.015","article-title":"Histone modifications in epigenetic regulation of cancer: perspectives and achieved progress","volume":"83","author":"Neganova","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.canlet.2023.216121_bib11","series-title":"Histone Deacetylases: the Biology and Clinical Implication","first-page":"13","article-title":"The biology of HDAC in cancer: the nuclear and epigenetic components","author":"Hagelkruys","year":"2011"},{"issue":"1","key":"10.1016\/j.canlet.2023.216121_bib12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41392-019-0095-0","article-title":"Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials","volume":"4","author":"Cheng","year":"2019","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"12","key":"10.1016\/j.canlet.2023.216121_bib13","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1111\/bcp.14889","article-title":"Recent developments of HDAC inhibitors: emerging indications and novel molecules","volume":"87","author":"Bondarev","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.canlet.2023.216121_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: from mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"issue":"16","key":"10.1016\/j.canlet.2023.216121_bib15","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.2217\/imt-2017-0134","article-title":"Modulation of antitumor immunity with histone deacetylase inhibitors","volume":"9","author":"McCaw","year":"2017","journal-title":"Immunotherapy"},{"issue":"22","key":"10.1016\/j.canlet.2023.216121_bib16","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1111\/febs.13746","article-title":"How do tumor cells respond to HDAC inhibition?","volume":"283","author":"Newbold","year":"2016","journal-title":"FEBS J."},{"issue":"1","key":"10.1016\/j.canlet.2023.216121_bib17","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1186\/s12916-022-02598-5","article-title":"Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors","volume":"20","author":"Zhang","year":"2022","journal-title":"BMC Med."},{"issue":"588","key":"10.1016\/j.canlet.2023.216121_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz6804","article-title":"A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma","volume":"13","author":"Yang","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.canlet.2023.216121_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/cddiscovery.2017.2","article-title":"Haematopoietic stem cells: past, present and future","volume":"3","author":"Ng","year":"2017","journal-title":"Cell Death Discov."},{"issue":"12","key":"10.1016\/j.canlet.2023.216121_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2012.08.003","article-title":"Valproic acid triggers erythro\/megakaryocyte lineage decision through induction of GFI1B and MLLT3 expression","volume":"40","author":"Zini","year":"2012","journal-title":"Exp. Hematol."},{"issue":"2","key":"10.1016\/j.canlet.2023.216121_bib21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bcp.2014.07.035","article-title":"Valproic acid regulates erythro-megakaryocytic differentiation through the modulation of transcription factors and microRNA regulatory micro-networks","volume":"92","author":"Tr\u00e9cul","year":"2014","journal-title":"Biochem. Pharmacol."},{"issue":"7","key":"10.1016\/j.canlet.2023.216121_bib22","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1158\/0008-5472.CAN-04-3011","article-title":"Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells","volume":"65","author":"Bug","year":"2005","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.canlet.2023.216121_bib23","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.3324\/haematol.2009.008870","article-title":"Histone deacetylase inhibition modulates cell fate decisions during myeloid differentiation","volume":"95","author":"Bartels","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.canlet.2023.216121_bib24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0166-2236(03)00031-6","article-title":"Stem and progenitor cells: the premature desertion of rigorous definitions","volume":"26","author":"Seaberg","year":"2003","journal-title":"Trends Neurosci."},{"issue":"8","key":"10.1016\/j.canlet.2023.216121_bib25","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/eji.201344150","article-title":"Dendritic cell development requires histone deacetylase activity","volume":"44","author":"Chauvistr\u00e9","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.canlet.2023.216121_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.749190","article-title":"The role of plasmacytoid dendritic cells in cancers","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.canlet.2023.216121_bib27","doi-asserted-by":"crossref","first-page":"e1139","DOI":"10.1002\/cti2.1139","article-title":"Plasmacytoid dendritic cell biology and its role in immune-mediated diseases","volume":"9","author":"Ye","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.canlet.2023.216121_bib28","series-title":"Kuby Immunology","year":"2013"},{"key":"10.1016\/j.canlet.2023.216121_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural killer cells: development, maturation, and clinical utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.canlet.2023.216121_bib30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/2159-8290.CD-20-0655","article-title":"Tumor-infiltrating natural killer cells","volume":"11","author":"C\u00f3zar","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2023.216121_bib31","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bbrc.2020.11.001","article-title":"Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function","volume":"534","author":"Watters","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.canlet.2023.216121_bib32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1189\/jlb.0711339","article-title":"Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression","volume":"91","author":"Rossi","year":"2012","journal-title":"J. Leukoc. Biol."},{"issue":"8","key":"10.1016\/j.canlet.2023.216121_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005782","article-title":"Histone deacetylase inhibitors enhance CD4 T cell susceptibility to NK cell killing but reduce NK cell function","volume":"12","author":"Pace","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.canlet.2023.216121_bib34","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3389\/fimmu.2016.00356","article-title":"HIV latency-reversing agents have diverse effects on natural killer cell function","volume":"7","author":"Garrido","year":"2016","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.canlet.2023.216121_bib35","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.febslet.2007.02.045","article-title":"Histone deacetylase inhibitors suppress natural killer cell cytolytic activity","volume":"581","author":"Ogbomo","year":"2007","journal-title":"FEBS Lett."},{"issue":"8","key":"10.1016\/j.canlet.2023.216121_bib36","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1128\/JVI.05545-11","article-title":"The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5\/T-BET signaling and generation of gamma interferon","volume":"86","author":"Alvarez-Breckenridge","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.canlet.2023.216121_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2013.00099","article-title":"Influence of histone deacetylase inhibitors and DNA-methyltransferase inhibitors on the NK cell-mediated lysis of pediatric B-lineage leukemia","volume":"3","author":"Pfeiffer","year":"2013","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2023.216121_bib38","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","article-title":"Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity","volume":"69","author":"Ning","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"20","key":"10.1016\/j.canlet.2023.216121_bib39","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.18632\/oncotarget.27546","article-title":"Entinostat augments NK cell functions via epigenetic upregulation of IFIT1-STING-STAT4 pathway","volume":"11","author":"Idso","year":"2020","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.canlet.2023.216121_bib40","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1038\/s41598-019-42237-3","article-title":"Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells","volume":"9","author":"Knox","year":"2019","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.canlet.2023.216121_bib41","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/QAD.0000000000002112","article-title":"In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals","volume":"33","author":"Garrido","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.canlet.2023.216121_bib42","unstructured":"Holtmeier W, Kabelitz D. \u0393\u03b4 T Cells Link Innate and Adaptive Immune Responses."},{"key":"10.1016\/j.canlet.2023.216121_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2013.00182","article-title":"IL-1 and T Helper immune responses","volume":"4","author":"Santarlasci","year":"2013","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.canlet.2023.216121_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/cancers8030036","article-title":"Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy","volume":"8","author":"Golubovskaya","year":"2016","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.canlet.2023.216121_bib45","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41577-018-0037-z","article-title":"Histone deacetylase function in CD4+ T cells","volume":"18","author":"Ellmeier","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"14","key":"10.1016\/j.canlet.2023.216121_bib46","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.7150\/jca.44622","article-title":"HDAC inhibitor, CG-745, enhances the anti-cancer effect of anti-PD-1 immune checkpoint inhibitor by modulation of the immune microenvironment","volume":"11","author":"Kim","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.canlet.2023.216121_bib47","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2407-3-30","article-title":"The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses","volume":"3","author":"Moreira","year":"2003","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.canlet.2023.216121_bib48","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.intimp.2006.07.001","article-title":"Histone deacetylase inhibitors induce antigen specific anergy in lymphocytes: a comparative study","volume":"6","author":"Edens","year":"2006","journal-title":"Int. Immunopharm."},{"issue":"11","key":"10.1016\/j.canlet.2023.216121_bib49","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.intimp.2009.07.012","article-title":"Histone deacetylase inhibitor uses p21(Cip1) to maintain anergy in CD4+ T cells","volume":"9","author":"Dagtas","year":"2009","journal-title":"Int. Immunopharm."},{"issue":"49","key":"10.1016\/j.canlet.2023.216121_bib50","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1038\/onc.2015.46","article-title":"Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity","volume":"34","author":"Cao","year":"2015","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.canlet.2023.216121_bib51","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s40425-019-0745-3","article-title":"Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)","volume":"7","author":"Bretz","year":"2019","journal-title":"J. Immunother. Canc."},{"issue":"12","key":"10.1016\/j.canlet.2023.216121_bib52","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1007\/s00262-019-02430-9","article-title":"Histone deacetylase inhibition promotes intratumoral CD8(+) T-cell responses, sensitizing murine breast tumors to anti-PD1","volume":"68","author":"McCaw","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"issue":"9","key":"10.1016\/j.canlet.2023.216121_bib53","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1074\/jbc.M113.517599","article-title":"Histone deacetylase inhibitors modulate interleukin 6-dependent CD4+ T cell polarization in vitro and in vivo","volume":"289","author":"Glauben","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.canlet.2023.216121_bib54","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.bcp.2007.05.002","article-title":"Disruption of HDAC4\/N-CoR complex by histone deacetylase inhibitors leads to inhibition of IL-2 gene expression","volume":"74","author":"Matsuoka","year":"2007","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.canlet.2023.216121_bib55","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/nm1652","article-title":"Deacetylase inhibition promotes the generation and function of regulatory T cells","volume":"13","author":"Tao","year":"2007","journal-title":"Nat. Med."},{"issue":"24","key":"10.1016\/j.canlet.2023.216121_bib56","doi-asserted-by":"crossref","first-page":"16313","DOI":"10.1021\/acs.jmedchem.2c01132","article-title":"Development of alkylated hydrazides as highly potent and selective class I histone deacetylase inhibitors with T cell modulatory properties","volume":"65","author":"Sun","year":"2022","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.canlet.2023.216121_bib57","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/s41375-018-0062-8","article-title":"Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors","volume":"32","author":"Bae","year":"2018","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.canlet.2023.216121_bib58","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1158\/2159-8290.CD-16-1020","article-title":"Synergistic immunostimulatory effects and therapeutic benefit of combined histone deacetylase and bromodomain inhibition in non-small cell lung cancer","volume":"7","author":"Adeegbe","year":"2017","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.canlet.2023.216121_bib59","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.4049\/jimmunol.1001101","article-title":"Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10","volume":"186","author":"Wang","year":"2011","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.canlet.2023.216121_bib60","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1189\/jlb.6A0617-217R","article-title":"Differentiation stage-specific effect of histone deacetylase inhibitors on the expression of ROR\u03b3T in human lymphocytes","volume":"102","author":"Sa\u0142kowska","year":"2017","journal-title":"J. Leukoc. Biol."},{"issue":"5","key":"10.1016\/j.canlet.2023.216121_bib61","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1158\/2326-6066.CIR-13-0188","article-title":"Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function","volume":"2","author":"Wong","year":"2014","journal-title":"Canc. Immunol. Res."},{"issue":"7","key":"10.1016\/j.canlet.2023.216121_bib62","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/cas.14069","article-title":"Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?","volume":"110","author":"Ohue","year":"2019","journal-title":"Cancer Sci."},{"issue":"7","key":"10.1016\/j.canlet.2023.216121_bib63","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1182\/blood-2018-05-847624","article-title":"Low-dose chidamide restores immune tolerance in ITP in mice and humans","volume":"133","author":"Zhao","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2023.216121_bib64","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/9678098","article-title":"Exploring the drug repurposing versatility of valproic acid as a multifunctional regulator of innate and adaptive immune cells","volume":"2019","author":"Soria-Castro","year":"2019","journal-title":"J. Immunol. Res."},{"issue":"17","key":"10.1016\/j.canlet.2023.216121_bib65","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1158\/1078-0432.CCR-17-0741","article-title":"Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma","volume":"23","author":"Orillion","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2023.216121_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030815","article-title":"Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models","volume":"7","author":"Shen","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.canlet.2023.216121_bib67","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13075-017-1357-2","article-title":"Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro","volume":"19","author":"Oh","year":"2017","journal-title":"Arthritis Res. Ther."},{"issue":"3","key":"10.1016\/j.canlet.2023.216121_bib68","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.clim.2010.04.018","article-title":"Histone\/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs","volume":"136","author":"Akimova","year":"2010","journal-title":"Clin. Immunol."},{"issue":"3","key":"10.1016\/j.canlet.2023.216121_bib69","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00262-016-1935-1","article-title":"Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro","volume":"66","author":"Wang","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2023.216121_bib70","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40360-015-0012-2","article-title":"Effects of cytarabine on activation of human T cells - cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid","volume":"16","author":"Ersvaer","year":"2015","journal-title":"BMC Pharmacol. Toxicol."},{"issue":"34","key":"10.1016\/j.canlet.2023.216121_bib71","doi-asserted-by":"crossref","first-page":"28656","DOI":"10.1074\/jbc.M112.356584","article-title":"The antiepileptic drug valproic acid restores T cell homeostasis and ameliorates pathogenesis of experimental autoimmune encephalomyelitis","volume":"287","author":"Lv","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"15 Pt 1","key":"10.1016\/j.canlet.2023.216121_bib72","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1158\/1078-0432.CCR-07-0014","article-title":"Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma","volume":"13","author":"Kato","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.canlet.2023.216121_bib73","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1242\/jcs.180885","article-title":"HDAC6 regulates the dynamics of lytic granules in cytotoxic T lymphocytes","volume":"129","author":"N\u00fa\u00f1ez-Andrade","year":"2016","journal-title":"J. Cell Sci."},{"issue":"6","key":"10.1016\/j.canlet.2023.216121_bib74","first-page":"955","article-title":"Valproic acid triggers radiation-induced abscopal effect by modulating the unirradiated tumor immune microenvironment in a rat model of breast cancer","volume":"62","author":"Jin","year":"2021","journal-title":"J. Radiat. Res."},{"issue":"5","key":"10.1016\/j.canlet.2023.216121_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/cells9051305","article-title":"\u0393\u03b4 T cells: the ideal tool for cancer immunotherapy","volume":"9","author":"Yazdanifar","year":"2020","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.canlet.2023.216121_bib76","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/cmi.2015.28","article-title":"The promise of \u03b3\u03b4 T cells and the \u03b3\u03b4 T cell receptor for cancer immunotherapy","volume":"12","author":"Legut","year":"2015","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.canlet.2023.216121_bib77","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cellimm.2015.01.019","article-title":"Modulation of human gamma\/delta T-cell activation and phenotype by histone deacetylase inhibitors","volume":"296","author":"Bhat","year":"2015","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.canlet.2023.216121_bib78","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3389\/fimmu.2018.01615","article-title":"Checkpoint blockade rescues the repressive effect of histone deacetylases inhibitors on \u03b3\u03b4 T cell function","volume":"9","author":"Bhat","year":"2018","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.canlet.2023.216121_bib79","doi-asserted-by":"crossref","first-page":"5933","DOI":"10.4049\/jimmunol.1401702","article-title":"Histone deacetylase inhibitors upregulate B cell microRNAs that silence AID and Blimp-1 expression for epigenetic modulation of antibody and autoantibody responses","volume":"193","author":"White","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2023.216121_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00627","article-title":"Genome-wide analysis reveals selective modulation of microRNAs and mRNAs by histone deacetylase inhibitor in B cells induced to undergo class-switch DNA recombination and plasma cell differentiation","volume":"6","author":"Shen","year":"2015","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.canlet.2023.216121_bib81","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1097\/TP.0000000000001197","article-title":"Modulation of donor-specific antibody production after organ transplantation by valproic acid: a histone deacetylase inhibitor","volume":"100","author":"Ye","year":"2016","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.canlet.2023.216121_bib82","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.jaci.2013.01.018","article-title":"Inhibition of human B-cell development into plasmablasts by histone deacetylase inhibitor valproic acid","volume":"131","author":"Kienzler","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.canlet.2023.216121_bib83","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40364-021-00333-5","article-title":"Landscape of myeloid-derived suppressor cell in tumor immunotherapy","volume":"9","author":"Hao","year":"2021","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.canlet.2023.216121_bib84","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00043426-200001000-00012","article-title":"Hematologic toxicity of sodium valproate","volume":"22","author":"Acharya","year":"2000","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2023.216121_bib85","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000028244","article-title":"Peripheral benzodiazepine receptor expression on leukocytes and neutrophil function during anticonvulsant monotherapy","volume":"57","author":"Caldiroli","year":"1998","journal-title":"Pharmacology"},{"issue":"4","key":"10.1016\/j.canlet.2023.216121_bib86","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/cdd.2012.154","article-title":"Gene expression signature-based approach identifies a pro-resolving mechanism of action for histone deacetylase inhibitors","volume":"20","author":"Montero-Melendez","year":"2013","journal-title":"Cell Death Differ."},{"issue":"2","key":"10.1016\/j.canlet.2023.216121_bib87","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.resuscitation.2011.07.029","article-title":"Effect of valproic acid on acute lung injury in a rodent model of intestinal ischemia reperfusion","volume":"83","author":"Kim","year":"2012","journal-title":"Resuscitation"},{"issue":"5","key":"10.1016\/j.canlet.2023.216121_bib88","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/SHK.0b013e3181a44c79","article-title":"Protective effect of suberoylanilide hydroxamic acid against LPS-induced septic shock in rodents","volume":"32","author":"Li","year":"2009","journal-title":"Shock"},{"key":"10.1016\/j.canlet.2023.216121_bib89","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1476-9255-7-9","article-title":"Histone deacetylase inhibitors induce apoptosis in human eosinophils and neutrophils","volume":"7","author":"Kankaanranta","year":"2010","journal-title":"J. Inflamm."},{"issue":"1","key":"10.1016\/j.canlet.2023.216121_bib90","first-page":"39","article-title":"Valproic acid-induced eosinophilic pleural effusion: a case report and review of the literature","volume":"18","author":"Kamenetsky","year":"2012","journal-title":"Neurol."},{"key":"10.1016\/j.canlet.2023.216121_bib91","series-title":"Kuby Immunology","year":"2019"},{"issue":"4","key":"10.1016\/j.canlet.2023.216121_bib92","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.exphem.2008.12.002","article-title":"Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL\/lpr(-\/-) murine model of autoimmune lymphoproliferative syndrome (ALPS)","volume":"37","author":"Dowdell","year":"2009","journal-title":"Exp. Hematol."},{"issue":"2 Suppl 2","key":"10.1016\/j.canlet.2023.216121_bib93","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jaci.2009.11.017","article-title":"IgE, mast cells, basophils, and eosinophils","volume":"125","author":"Stone","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.canlet.2023.216121_bib94","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.12627","article-title":"Human mast cells and basophils\u2014how are they similar how are they different?","volume":"282","author":"Varricchi","year":"2018","journal-title":"Immunol. Rev."},{"issue":"6","key":"10.1016\/j.canlet.2023.216121_bib95","doi-asserted-by":"crossref","first-page":"9647","DOI":"10.18632\/oncotarget.14181","article-title":"Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis","volume":"8","author":"Lyberg","year":"2017","journal-title":"Oncotarget"},{"issue":"9\u201310","key":"10.1016\/j.canlet.2023.216121_bib96","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.imbio.2010.05.023","article-title":"Trichostatin A blocks type I interferon production by activated plasmacytoid dendritic cells","volume":"215","author":"Salvi","year":"2010","journal-title":"Immunobiology"},{"key":"10.1016\/j.canlet.2023.216121_bib97","first-page":"152","article-title":"Targeting deacetylases to improve outcomes after allogeneic bone marrow transplantation","volume":"124","author":"Reddy","year":"2013","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"key":"10.1016\/j.canlet.2023.216121_bib98","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3389\/fphar.2018.00612","article-title":"Trichostatin a protects dendritic cells against oxygen-glucose deprivation via the SRSF3\/PKM2\/glycolytic pathway","volume":"9","author":"Jiang","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.canlet.2023.216121_bib99","doi-asserted-by":"crossref","first-page":"G1384","DOI":"10.1152\/ajpgi.00540.2011","article-title":"Butyrate increases IL-23 production by stimulated dendritic cells","volume":"303","author":"Berndt","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"7","key":"10.1016\/j.canlet.2023.216121_bib100","first-page":"2562","article-title":"Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice","volume":"118","author":"Reddy","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.canlet.2023.216121_bib101","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.imbio.2011.11.010","article-title":"Impact of valproic acid on dendritic cells function","volume":"217","author":"Frikeche","year":"2012","journal-title":"Immunobiology"},{"issue":"9","key":"10.1016\/j.canlet.2023.216121_bib102","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20092241","article-title":"Immunoepigenetics combination therapies: an overview of the role of HDACs in cancer immunotherapy","volume":"20","author":"Banik","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.canlet.2023.216121_bib103","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-05-284711","article-title":"Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection","volume":"117","author":"Roger","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.canlet.2023.216121_bib104","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/039463200902200227","article-title":"Apicidin, the histone deacetylase inhibitor, suppresses Th1 polarization of murine bone marrow-derived dendritic cells","volume":"22","author":"Jung","year":"2009","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"5","key":"10.1016\/j.canlet.2023.216121_bib105","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1158\/2326-6066.CIR-21-0170","article-title":"Entinostat decreases immune suppression to promote antitumor responses in a HER2+ breast tumor microenvironment","volume":"10","author":"Sidiropoulos","year":"2022","journal-title":"Canc. Immunol. Res."},{"issue":"9","key":"10.1016\/j.canlet.2023.216121_bib106","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s00262-020-02588-7","article-title":"Selective targeting of different populations of myeloid-derived suppressor cells by histone deacetylase inhibitors","volume":"69","author":"Hashimoto","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"issue":"6","key":"10.1016\/j.canlet.2023.216121_bib107","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1164919","article-title":"Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma","volume":"5","author":"Kroesen","year":"2016","journal-title":"OncoImmunology"},{"issue":"3","key":"10.1016\/j.canlet.2023.216121_bib108","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00262-017-2091-y","article-title":"The class I\/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy","volume":"67","author":"Briere","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"issue":"12","key":"10.1016\/j.canlet.2023.216121_bib109","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/2326-6066.CIR-18-0070","article-title":"Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs","volume":"6","author":"Christmas","year":"2018","journal-title":"Canc. Immunol. Res."},{"issue":"7798","key":"10.1016\/j.canlet.2023.216121_bib110","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41586-020-2054-x","article-title":"Epigenetic therapy inhibits metastases by disrupting premetastatic niches","volume":"579","author":"Lu","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.canlet.2023.216121_bib111","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.surg.2013.04.003","article-title":"Novel pharmacologic treatment attenuates septic shock and improves long-term survival","volume":"154","author":"Zhao","year":"2013","journal-title":"Surgery"},{"issue":"4","key":"10.1016\/j.canlet.2023.216121_bib112","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s12272-009-1418-4","article-title":"Anti-inflammatory effect of Trichostatin-A on murine bone marrow-derived macrophages","volume":"32","author":"Han","year":"2009","journal-title":"Arch Pharm. Res. (Seoul)"},{"issue":"Suppl","key":"10.1016\/j.canlet.2023.216121_bib113","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.ijantimicag.2013.04.004","article-title":"Epigenetics in sepsis: targeting histone deacetylases","volume":"42","author":"Ciarlo","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"5","key":"10.1016\/j.canlet.2023.216121_bib114","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3858\/emm.2008.40.5.574","article-title":"Histone deacetylase inhibitor KBH-A42 inhibits cytokine production in RAW 264.7 macrophage cells and in vivo endotoxemia model","volume":"40","author":"Choi","year":"2008","journal-title":"Exp. Mol. Med."},{"issue":"4","key":"10.1016\/j.canlet.2023.216121_bib115","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1089\/dna.2011.1401","article-title":"Histone deacetylase inhibition by sodium valproate regulates polarization of macrophage subsets","volume":"31","author":"Wu","year":"2012","journal-title":"DNA Cell Biol."},{"issue":"17","key":"10.1016\/j.canlet.2023.216121_bib116","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21175966","article-title":"Trichostatin A alleviates renal interstitial fibrosis through modulation of the M2 macrophage subpopulation","volume":"21","author":"Tseng","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2023.216121_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105973","article-title":"Trichostatin A modulates the macrophage phenotype by enhancing autophagy to reduce inflammation during polymicrobial sepsis","volume":"77","author":"Cui","year":"2019","journal-title":"Int. Immunopharm."},{"issue":"7645","key":"10.1016\/j.canlet.2023.216121_bib118","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nature21409","article-title":"Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages","volume":"543","author":"Guerriero","year":"2017","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.canlet.2023.216121_bib119","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1007\/s10753-018-0853-0","article-title":"Protective effect of tubastatin A in CLP-induced lethal sepsis","volume":"41","author":"Deng","year":"2018","journal-title":"Inflammation"},{"issue":"9","key":"10.1016\/j.canlet.2023.216121_bib120","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/infdis\/jir553","article-title":"Histone deacetylase inhibitors impair antibacterial defenses of macrophages","volume":"204","author":"Mombelli","year":"2011","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.canlet.2023.216121_bib121","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1128\/AAC.01876-15","article-title":"Histone deacetylase inhibitors promote mitochondrial reactive oxygen species production and bacterial clearance by human macrophages","volume":"60","author":"Ariffin","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.canlet.2023.216121_bib122","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00092","article-title":"Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi","volume":"8","author":"Suraweera","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2023.216121_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2020.578011","article-title":"Synergistic enhancement of cancer therapy using HDAC inhibitors: opportunity for clinical trials","volume":"11","author":"Hontecillas-Prieto","year":"2020","journal-title":"Front. Genet."},{"issue":"10","key":"10.1016\/j.canlet.2023.216121_bib124","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.clon.2013.06.007","article-title":"Biological consequences of radiation-induced DNA damage: relevance to radiotherapy","volume":"25","author":"Lomax","year":"2013","journal-title":"Clin. Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2023.216121_bib125","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/bjc.2013.21","article-title":"Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair","volume":"108","author":"Groselj","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"13","key":"10.1016\/j.canlet.2023.216121_bib126","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.3390\/ijms20133259","article-title":"Comparison of radiosensitization by HDAC inhibitors CUDC-101 and SAHA in pancreatic cancer cells","volume":"20","author":"Moertl","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.canlet.2023.216121_bib127","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3892\/or.2015.4089","article-title":"Inhibitory effects of valproic acid in DNA double-strand break repair after irradiation in esophageal squamous carcinoma cells","volume":"34","author":"Makita","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2023.216121_bib128","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/4936207","article-title":"Chidamide and radiotherapy synergistically induce cell apoptosis and suppress tumor growth and cancer stemness by regulating the MiR-375-EIF4G3 Axis in lung squamous cell carcinomas","volume":"2021","author":"Huang","year":"2021","journal-title":"J. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2023.216121_bib129","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.radonc.2013.08.023","article-title":"The novel HDAC inhibitor NDACI054 sensitizes human cancer cells to radiotherapy","volume":"109","author":"Hehlgans","year":"2013","journal-title":"Radiother. Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2023.216121_bib130","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(10)70058-9","article-title":"Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study","volume":"11","author":"Ree","year":"2010","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2023.216121_bib131","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1097\/CAD.0000000000000282","article-title":"Phase I study evaluating the safety and efficacy of oral panobinostat in combination with radiotherapy or chemoradiotherapy in patients with inoperable stage III non-small-cell lung cancer","volume":"26","author":"Takhar","year":"2015","journal-title":"Anti Cancer Drugs"},{"issue":"1","key":"10.1016\/j.canlet.2023.216121_bib132","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1365-2133.2012.10905.x","article-title":"Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions","volume":"167","author":"Akilov","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.canlet.2023.216121_bib133","series-title":"StatPearls","article-title":"Cancer chemotherapy","author":"Amjad","year":"2022"},{"issue":"12","key":"10.1016\/j.canlet.2023.216121_bib134","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-15-0077-T","article-title":"HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade","volume":"3","author":"Woods","year":"2015","journal-title":"Canc. Immunol. Res."},{"issue":"23","key":"10.1016\/j.canlet.2023.216121_bib135","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.7150\/jca.34471","article-title":"Histone deacetylase inhibition up-regulates MHC class I to facilitate cytotoxic T lymphocyte-mediated tumor cell killing in glioma cells","volume":"10","author":"Sun","year":"2019","journal-title":"J. Cancer"},{"issue":"5","key":"10.1016\/j.canlet.2023.216121_bib136","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.molonc.2015.12.012","article-title":"Essential role of HDAC6 in the regulation of PD-L1 in melanoma","volume":"10","author":"L","year":"2016","journal-title":"Mol. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2023.216121_bib137","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00262-018-2283-0","article-title":"Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model","volume":"68","author":"Llopiz","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"issue":"8","key":"10.1016\/j.canlet.2023.216121_bib138","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1158\/2326-6066.CIR-18-0875","article-title":"Histone deacetylase inhibition sensitizes PD1 blockade\u2013resistant B-cell LymphomasCombination HDACi and anti-PD1 effective for B-cell lymphoma","volume":"7","author":"Wang","year":"2019","journal-title":"Canc. Immunol. Res."},{"issue":"69","key":"10.1016\/j.canlet.2023.216121_bib139","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.23169","article-title":"HDAC inhibition potentiates immunotherapy in triple negative breast cancer","volume":"8","author":"Terranova-Barberio","year":"2017","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.canlet.2023.216121_bib140","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1158\/1078-0432.CCR-19-1305","article-title":"Phase I\/ib study of pembrolizumab plus vorinostat in advanced\/metastatic non\u2013small cell lung cancer","volume":"25","author":"Gray","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.canlet.2023.216121_bib141","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.3390\/ph3092751","article-title":"Clinical toxicities of histone deacetylase inhibitors","volume":"3","author":"Subramanian","year":"2010","journal-title":"Pharmaceuticals"},{"issue":"8","key":"10.1016\/j.canlet.2023.216121_bib142","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.3390\/ijms19082337","article-title":"The therapeutic strategy of HDAC6 inhibitors in lymphoproliferative disease","volume":"19","author":"Cosenza","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.canlet.2023.216121_bib143","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13148-021-01098-2","article-title":"Predictive biomarkers and potential drug combinations of epi-drugs in cancer therapy","volume":"13","author":"Yang","year":"2021","journal-title":"Clin. Epigenet."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383523000721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383523000721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:08:44Z","timestamp":1759594124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383523000721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":143,"alternative-id":["S0304383523000721"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216121","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216121","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"216121"}}